Journal articles on the topic 'Komagome (Tokyo)'
To see the other types of publications on this topic, follow the link: Komagome (Tokyo).
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 19 journal articles for your research on the topic 'Komagome (Tokyo).'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Negishi, Masayoshi. "HIV/AIDS Care at Tokyo Metropolitan Komagome Hospital." Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 14 (1997): S35—S37. http://dx.doi.org/10.1097/00042560-199700002-00007.
Full text
2
Masuda, G., A. Ajisawa, M. Negishi, A. Imamura, Y. Inamura, H. Tachibana, T. Takeuchi, and M. Saito. "Entamoeba histolytica/dispar infections in HIV-positive individuals presented at Tokyo Metropolitan Komagome Hospital, Tokyo." Parasitology International 47 (August 1998): 199. http://dx.doi.org/10.1016/s1383-5769(98)80518-7.
Full text
3
YASUNO, Akira, Seizo UCHIDA, Hiroshi YAMAGUCHI, Yuichi INOUE, Etsuko YANAGIHA, and Mihoko KUBOTA. "THE CONSTRUCTION PROCESS AND DESIGN OF A REINFORCED CONCRETE APARTMENT BUILDING IN KOMAGOME, TOKYO (1938)." Journal of Architecture and Planning (Transactions of AIJ) 71, no. 600 (2006): 203–9. http://dx.doi.org/10.3130/aija.71.203_2.
Full text
4
Ebara, T., K. Karasawa, K. Maebayashi, H. Kurosaki, H. Ishikawa, T. Kaizu, Y. Tanaka, K. Akagi, and G. Masuda. "Radiation therapy for Kaposi's sarcoma associated with acquired immunodeficiency syndrome: Tokyo Metropolitan Komagome Hospital experience." International Journal of Clinical Oncology 5, no. 6 (December 20, 2000): 395–98. http://dx.doi.org/10.1007/pl00012069.
Full text
5
Suzuki, C., G. Masuda, S. Kano, and M. Suzuki. "Clinical and in vitro efficacy of anti-malarial drugs on 16 Plasmodium falciparum malaria experienced at Tokyo metropolitan Komagome hospital, Tokyo, Japan." Parasitology International 47 (August 1998): 237. http://dx.doi.org/10.1016/s1383-5769(98)80643-0.
Full text
6
Hoshino, Yoshihiko, Gohta Masuda, Masayoshi Negishi, Atsushi Ajisawa, Akifumi Imamura, Kei Hachimori, Naohide Takayama, Tsuyoshi Yamaguchi, and Mikio Kimura. "Clinical and Bacteriological Profiles of Patients with Typhoid Fever Treated during 1975-1998 in the Tokyo Metropolitan Komagome Hospital." Microbiology and Immunology 44, no. 7 (July 2000): 577–83. http://dx.doi.org/10.1111/j.1348-0421.2000.tb02536.x.
Full text
7
Nakajima, Yasushi, Akane Yoshida, and Tsuyoshi Kato. "Report on the Project on the Implementation of Continuity Operations in Disaster-Affected Healthcare Facilities Using Gensai Calendar HDMG and COOP Flow Diagram." Journal of Disaster Research 18, no. 2 (February 1, 2023): 114–23. http://dx.doi.org/10.20965/jdr.2023.p0114.
Full textAbstract:
Based on the lessons learned from past disasters, the Japanese Ministry of Health, Labour and Welfare has notified the establishment of disaster base hospitals and ensured medical care continuity based on business continuity plan (BCP). Following these, we created a disaster management training program with 45 items, the Disaster Mitigation (Gensai) Calendar for Healthcare Disaster Management Guide (HDMG)* (“Gensai Calendar”) in 2018. Thereafter, a three-year multicenter project was launched at the Tokyo Metropolitan Hospital Organization to introduce the “Gensai Calendar” and assess its merits as a self-learning material through tests based on it. The project also aimed at establishing a common operating procedure (COOP) for medical continuity at affected healthcare facilities using annual comprehensive disaster drills. The numbers of participants and hospitals recruited for the test over the three-year period were 4,281 in six hospitals, 6,179 in ten hospitals, and 6,216 in seven hospitals. The total of 55 questions were asked in the e-learning format in the first and second years, and 11 in the third year. Questions with less than 70% correct rate were same for three years. Through the drills, a COOP flow diagram was constructed based on the initial responses in the wards. Furthermore, the crisis management system of each hospital was unified, and each BCP was revised into a standard document along the “COOP Flow Diagram.” A COOP system combining the “Gensai Calendar” learnings, annual “COOP Flow Diagram” drill, and standard documentation can be a viable system for medical continuity. This system could also be versatile and introduced to many healthcare facilities. * This is also the abbreviation for the Hiroo Disaster Management Group, which has a double meaning. The group consists of disaster prevention staff from the Tokyo Metropolitan Hiroo Hospital, Komagome Hospital, and Bokutoh Hospital, and is responsible for planning and managing disaster mitigation measures.
8
KAMINUMA, Takuya, Katsuyuki KARASAWA, Nahoko HANYU, Ta-Chen CHANG, Gencho KUGA, Naoko OKANO, Nobuteru KUBO, et al. "Acute Adverse Effects of Radiation Therapy on HIV-positive Patients in Japan: Study of 31 Cases at Tokyo Metropolitan Komagome Hospital." Journal of Radiation Research 51, no. 6 (2010): 749–53. http://dx.doi.org/10.1269/jrr.10090.
Full text
9
Kobayashi, Takeshi, Takuya Yamashita, Miwa Sakai, Yoshiki Okuyama, Kazuteru Ohashi, Hideki Akiyama, Kiyoshi Hiruma, and Hisashi Sakamaki. "Single-Institute Analysis of Allogeneic Stem Cell Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia." Blood 106, no. 11 (November 16, 2005): 5445. http://dx.doi.org/10.1182/blood.v106.11.5445.5445.
Full textAbstract:
Abstract Purpose We report the outcomes of allogeneic stem cell transplantation (SCT) for the patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) in a single center. Patients and Methods Between August 1993 and March 2005, 36 patients with Ph+ALL received SCT at Tokyo Metropolitan Komagome Hospital. The median age was 41 years (range; 17 to 60 years). All patients received myeloablative conditioning regimen (cytosine arabinoside, cyclophosphamide and fractionated 12Gy total-body irradiation). Stem cell source of SCT was 14 related donors (bone marrow [n=9] and peripheral blood stem cell [n=5]) and 22 unrelated donors (bone marrow [n=13] and cord blood [n=9]). Results Seventeen (47%) of 36 patients are alive at a median of 2.16 years (range; 1.0 to 3.3 years) after transplantation. Three years overall survival (OS) and disease free survival (DFS) for all patients are 42.3% and 35.4%, respectively. Three years OS and DFS are 55.4% and 46.4% for the 24 patients in complete remission (CR) at transplantation, while 36.4% (p<0.001) and 16.7% (p<0.01) for the 12 patients in non-CR, respectively. Stem cell source and patients age do not affect the outcomes. The higher white blood cell counts at diagnosis are associated with poor OS (p=0.003). The median duration from diagnosis to SCT is 7 months (range; 3 to 29 months). Three years OS of the patients who received SCT within 7 months from diagnosis is better than that of the others (59.3% vs. 31.1%, p=0.019). Conclusion This analysis suggests that shorter duration between diagnosis and transplantation improve the clinical outcomes of SCT for Ph+ALL, especially performed in CR.
10
Takagi, Maki, Misato Takao, Nozomi Funatsu, Soichiro Natsume, Daisuke Nakano, Kazushige Kawai, and Tatsuro Yamaguchi. "Clinicopathologic characteristics of patients with early-onset colorectal cancer." Journal of Clinical Oncology 42, no. 3_suppl (January 20, 2024): 74. http://dx.doi.org/10.1200/jco.2024.42.3_suppl.74.
Full textAbstract:
74 Background: Although the incidence of colorectal cancer has been declining in the United States in recent years, the incidence of young patients under 50 years of age has been reported to be increasing by several percent per year. Various studies have been conducted to characterize early-onset colorectal cancer (EO-CRC); however, it has been unclear whether it is a different entity from late-onset colorectal cancer (LO-CRC). In this study, we evaluated the clinicopathologic characteristics of EO-CRC in Japan. Methods: This study included 1,336 patients who underwent surgical resection for colorectal cancer at Tokyo Metropolitan Komagome Hospital from January 2015 to December 2019. We performed genetic testing for patients with suspected Lynch syndrome after providing genetic counseling and obtaining informed consent. The study protocol was approved by the Institutional Review Board. Results: Of the 1,336 colorectal cancer patients, 117 (8.9%) had EO-CRC with a median age at the diagnosis of 44 (17–49) years. Tumors were located at right-sided colon in 23 patients and left-sided colorectum in 92 patients with EO-CRC, respectively. The clinical stage of the tumor was I in 19, II in 23, III in 50, and IV in 23 patients with EO-CRC, respectively. Histologically, differentiated type, undifferentiated type, and mucinous carcinoma were 106, 5, and 3 patients, respectively. KRAS mutation was detected in 25.0% and BRAF V600E was detected in 4.3% of patients with EO-CRC. In the microsatellite status, MSI-High was detected in 6 (5.1%) patients with EO-CRC, of whom 3 (2.6%) were diagnosed with Lynch syndrome by genetic testing. Causative genes were MLH1 in 2 patients and MSH2 in one patient. In hereditary tumors, 2 patients with familial adenomatous polyposis were included in addition to Lynch syndrome. On the other hand, 1,219 (91.2%) had LO-CRC with 34.5% of KRAS mutation and 6.4% of BRAFV600E. MSI-High was detected in 69(5.7%) patients with LO-CRC，of whom 5 (0.4%) were diagnosed with Lynch syndrome. Lynch syndrome was significantly more common in EO-CRC (p=0.026). Conclusions: The alterations of KRAS and BRAF tended to be more frequent in EO-CRC. The frequency of hereditary CRC was more frequent in EO-CRC than in LO-CRC.
11
Saji, S., N. Ishizuka, K. Horiguchi, E. Suzuki, H. Bando, T. Aruga, I. Takahashi, T. Tominaga, and M. Toi. "Age frequency distribution of joint ER/PR phenotypes in primary breast cancer patients: An analysis of 3,620 cases at a single Japanese institute." Journal of Clinical Oncology 24, no. 18_suppl (June 20, 2006): 597. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.597.
Full textAbstract:
597 Background: Hormone receptor (HR) expression may reflect the different subtypes of breast cancer. Recent clinical trials have reported that joint Estrogen receptor (ER)/Progesterone receptor (PR) phenotypes in breast cancer have specific spectrum for treatment response. To analyze the epidemiologic character of ER/PR subtypes in Japanese patients, a retrospective data survey was conducted for 3,620 breast cancer patients treated at a single institute during 1975–2005. Methods: Patients records were obtained from cancer registration of the Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital and analyzed with SAS software. Among 3,620 operated patients, data of ER/PR subtypes were available in 2,707 cases. HRs were evaluated by ligand binding assay (LBA) or enzyme immuno assay (EIA) from 1975 to 2000 (n=1721), and by immunohistochemistry (IHC) after that (n=986). Results: Both mean and median of patient’s age increased through the operated year (p<0.0001). Therefore, all analysis related to distribution of age were adjusted by the operated year. As reported before, ER+ population showed liner trend with age by LBA/EIA (p<0.0001), while this was not observed by IHC. ER-/PR+ population was 10.6% by LBA/EIA, whereas it decreased to 2.1% by IHC. These are due to the increase of ER+ population with IHC analysis, since marginal distribution between two methods in the patients tested by both assays was significantly different for ER, but not for PR (n=181, p=0.0038 and n=175, p=0.1944). Irrespective of assay methods, peak age frequency of ER+/PR+ was between 46 and 50 years of age, whereas that of ER+/PR- was 56–60. For ER/PR phenotypes there was a significant difference of odds ratio across the age (<55 vs. ≥55, p=0.04 for IHC, p=0.0002 for LBA/EIA). Conclusion: Changes of standard assay from LBA/EIA to IHC affected the population of ER+ and lead the decrease of ER-/PR+ subtype. Japanese women’s peak age frequency of ER+/PR+ was in the premenopausal period compared to that of non-Hispanic white women in the postmenopausal age (Anderson WF, JCO 2001). Difference of most frequent age of each subtype among the races may be taken into account for the development of chemoprevention strategy with anti-estrogens. No significant financial relationships to disclose.
12
Akiyama, Hideki, Wataru Munakata, Takeshi Kobayashi, Kazuhiko Kakihana, Takuya Yamashita, Kazuteru Ohashi, and Hisashi Sakamaki. "Morbidity and Mortality Later Than 2 Years After HSCT. A Sinle Institution Experience." Blood 116, no. 21 (November 19, 2010): 4508. http://dx.doi.org/10.1182/blood.v116.21.4508.4508.
Full textAbstract:
Abstract Abstract 4508 Long-term follow-up data of the patients who underwent HSCT more than 2 years ago at a single institution in Japan was presented. The patients who received first allogeneic hematopoietic stem cell transplantation (HSCT) at Tokyo Metropolitan Komagome Hospital between January, 1990 and December, 2007 under hematology division were included. Follow-up data were obtained annually from the medical records if the patients visited our institution regularly. If the patients were not followed in our institution, follow-up data were requested to the hospitals where the patients had been followed or questionnaires were sent directly to the patients unless their addresses are not known. These letters were sent annually. The most recent laboratory data and any kind of complications under treatment including hypertension, hyperlipidemia, diabetes including usage of insulin, renal failure, dialysis, and any kind of malignancies were requested to be reported. Survival was the most primitive data and the reason of death was defined by one of the authors, HA. Chronic GVHD was excluded from the independent etiology of death. Progression of the disease or complications of the treatment for the progressive disease were considered to be due to relapse. The incidence of each complication was calculated using the number of the patients whose data are available. In total, 622 patients had received transplantation and 370 patients survived more than 2 years. During last two years, 211 patients had been followed in our institution while 74 patients by the institutions outside. Letters were sent directly to rest of surviving patients. As the result, 6 patients could not be reached by any method. Letters had been received without response in 15 patients. 72 patients died later than 2 years after transplantation. Relapse was the most important reason of death even more than 2 years after the transplantation. Although the incidence declined annually, the latest relapse was observed in the patient with CML almost 15 years after the transplantation. Pulmonary complications including bronchiolitis obliterans and infections followed. Secondary malignancy was the reason of death in 7 patients. Chronic kidney disease was already observed in 27 % of the patients who survived 2 years after transplantation and one of the devastating complications. In total of 7 patients needed to start regular dialysis or kidney transplantation and another 2 patients showed eGFR level of less than 15 ml/min/m2. Nephrotic syndrome was another renal complication observed in 4 patients. Hypertension was reported on 46/244 (19%) of the patients. Diabetes was reported on 27/241 (11.2%) and 13 of them were on regular insulin treatment. Definitive diagnostic criteria of diabetes were not indicated on this analysis suggesting higher incidence of glucose intolerance in these patients. There were 14 patients developed secondary malignancies diagnosed later than 2 years after transplantation and oral mucosa, tongue, esophagus and colon were the main organs involved. Physicians taking care of those patients were recommended to check kidney function and gastrointestinal tract including head/neck, esophagus and colon for secondary malignancy, as well as hematological status. Disclosures: No relevant conflicts of interest to declare.
13
Tokisawa, Hiromi, Tomoyuki Aruga, Yayoi Honda, Toshiyuki Ishiba, Rika Yonekura, Naoko Iwamoto, and Yuichi Kumaki. "Abstract P4-07-25: Distant metastasis of breast cancer is triggered by changes in the dynamics of metastatic cells after removal of the primary lesion." Cancer Research 82, no. 4_Supplement (February 15, 2022): P4–07–25—P4–07–25. http://dx.doi.org/10.1158/1538-7445.sabcs21-p4-07-25.
Full textAbstract:
Abstract PURPOSE Breast cancer subtype influences the dynamics of distant recurrence. We investigated the timing of distant recurrence (distant disease-free interval DDFI) for each subtype and its relationship to stage, and perioperative treatment. PATIENTS AND METHODS We retrospectively analyzed data from 4,658 patients with stage I-III invasive breast cancer operated at Tokyo Metropolitan Komagome Hospital from 1998 to 2018. Patients were classified into five biological subtypes according to estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor 2 (HER2), and nuclear grade using immunohistochemistry findings: luminal A, luminal B/HER2-, luminal B/HER2+, HER2-enriched, Triple negative (TN). We investigated distant disease-free interval (DDFI) and analyzed the dynamics of distant metastasis. One-way analysis of variance was used to compare the recurrence patterns. RESULTS The median observation period was 6.3 years. Of the 4,051 patients for whom subtyping was possible, 422 developed distant recurrence. 5-year distant recurrence-free rates were 97.3% for luminal A, 86.8% for luminal B/HER2-, 89.1% for luminal B/HER2+, 84.6% for HER2-enriched, and 81 .7% for TN. In all subtypes, the recurrence rate increased with stage progression. The recurrence dynamics in luminal A showed a gradual peak at 3 years after starting treatment, after 5 years with more recurrences occurring than in other subtypes, especially late recurrences after 10 years. The median DDFI was 5.5 years (IQR 3.2-8.6 years). luminal B/HER2- and luminal B/HER2+ patients had similar recurrence dynamics, with peak recurrences at 2.4 and 2.3 years after starting treatment, respectively, followed by fewer recurrences over time, but recurrences were still observed after 5 years. Median DDFI was 3.1 years (IQR 1.9-5.9) and 2.9 years (IQR 1.9-5.9), respectively. HER2-enriched and TN showed similar recurrence dynamics, with a high peak of recurrence at 1.5 and 1.4 years, respectively, followed by a rapid decrease in recurrence and a rare recurrence after 5 years. The median DDFI was 1.8 years (IQR 1.1-2.5) and 1.6 years (IQR 1.1-2.9), respectively. When these recurrence dynamics were evaluated by stage for each subtype, the peak DDFI values for stage1, stage2, and stage3 were 3.4, 3.4, and 3.3 years for luminal A, 2.8, 2.7, and 2.1 years for luminal B/HER2-, 1.7, 2.2, and 2.6 years for luminal B/HER2+, 1.2,1.8, and 1.4 years for HER2-enriched, and 1.3,1.5, and 1.2 years for TN. There was no difference by stage for all subtypes (p=0.58, 0.25, 0.20, 0.74, and 0.26, respectively). Furthermore, the recurrence dynamics did not differ by the presence or absence of perioperative chemotherapy for each subtype (p=0.48, 0.31, 0.12, 0.34, and 0.09, respectively). Conclusion In all subtypes, distant metastasis incidence peaks between 1.5 and 3 years after surgery and then declines. The post-peak decline pattern showed characteristic dynamics for each subtype, but each peak in same subgroup was not associated with clinical stage or perioperative chemotherapy. Some kinds of the distant metastatic machinery may be caused by changes in the growth dynamics and microenvironment of distant cancer cells associated with primary tumor resection. Citation Format: Hiromi Tokisawa, Tomoyuki Aruga, Yayoi Honda, Toshiyuki Ishiba, Rika Yonekura, Naoko Iwamoto, Yuichi Kumaki. Distant metastasis of breast cancer is triggered by changes in the dynamics of metastatic cells after removal of the primary lesion [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P4-07-25.
14
Toya, Takashi, Ayumi Taguchi, Kazutaka Kitaura, Yuki Otsuka, Ryosuke Konuma, Hiroto Adachi, Atsushi Wada, et al. "Clonal Dynamics and Publicness of CMV-Specific TCR Repertoire after Allogeneic Stem Cell Transplantation." Blood 134, Supplement_1 (November 13, 2019): 4551. http://dx.doi.org/10.1182/blood-2019-122894.
Full textAbstract:
[Background] Cytomegalovirus (CMV) disease is a major complication after allogeneic stem cell transplantation (SCT). However, mechanisms of adoptive immunity against CMV are not fully elucidated. Recently, high-throughput next-generation sequencing (NGS) technology made it possible to shed light on the detailed and comprehensive landscape of T-cell receptor (TCR) repertoire. In this study, we analyzed TCR repertoire of CMV-specific cytotoxic T-cells (CMV-CTLs) in patients who suffered from CMV reactivation after SCT to clarify the diversity and dynamics of CMV-specific T-cell immunity. [Methods] We sequentially collected peripheral blood mononuclear cells from patients with HLA-A*24:02 who received SCT in our institution. Samples were collected weekly or every two weeks from their neutrophil engraftment until approximately 100 days after SCT. CMV reactivation was evaluated weekly with CMV antigenemia test. CD8 and CMV pp65 tetramer positive cells were sorted and unbiased next-generation sequencing-based analyses of TRBV/TRBJ gene segments were performed at the timing of CMV reactivation in 16 patients, and TRA gene segments were also analyzed in 10 patients. In addition, TCR beta repertoires after 2-4 weeks were analyzed in 12 patients. In the 12 patients, the dynamics of TCR repertoire diversity and proportional changes of each clone were assessed. We evaluated the diversity by Shannon-Weber index, and we defined TCR beta clonotypes found in two or more patients using the same TRBV/TRBJ gene segments and CDR3 amino acid sequences as public. This study was approved by the ethics committee of Tokyo Metropolitan Komagome Hospital. [Results] Among 16 patients, 11 received bone marrow, 3 received peripheral blood stem cells, and 2 received cord blood transplant. Underlying diseases were acute myeloid leukemia in 7, acute lymphoblastic leukemia in 7, and myelodysplastic syndromes in 2 patients. Median age at SCT was 50 years old (range: 20-71). Median duration from SCT to first CMV reactivation was 39 days (range: 16-55) and 7 patients (43.8%) were administered systemic corticosteroid at the time of reactivation (prednisolone 10-30mg/day). Median peripheral blood CMV-CTLs count at that time was 29.47/uL (range: 4.65-229.6). In most patients TCR beta repertoire of CMV-specific CTLs when CMV reactivated was highly skewed (median Shannon-Weber index was 1.44 [range: 0.542-3.164]). TCR alpha and beta were analyzed together in 10 patients and their diversity correlated well (p<0.001). Interestingly, 12 of 16 patients (75.0%) had at least one public TCR and, in all 12 patients with public TCR, the most frequent TCRs were public. Diversity of TCR repertoire was significantly lower in patients with public TCR compared with those in patients without (p=0.039). There was no obvious association between presence of public TCR and multiple events of CMV reactivation (p=0.57). When we evaluated clonal transition in 12 patients whose TCR beta repertoires were analyzed sequentially, the public clonotypes were continuously detected in 10 of 11 patients with public TCR and remained dominant in 9, while in one patient frequency of the most frequent public clone declined massively (from 50.25% among assigned reads to 6.63%). In addition, there were two patterns of subsequent clonal behavior in TCR repertoire of CMV-CTLs. In 10 patients, prevailing clones persisted and TCR repertoires of CMV-CTLs remained oligoclonal (Figure A). However, in other two patients, TCR repertoires of CMV-CTLs became more diverse (Shannon-Weber index at the time of reactivation and a few weeks after was 0.558/2.958 in one patient and 1.471/3.86 in another), major clones lost, and new private clones appeared afterwards (Figure B). Polyclonal pattern (TCR repertoire of CMV-CTLs was diverse at the time of reactivation or after a few weeks) was detected in 3 patients out of 16 patients, and the pattern was exclusively seen in patients who were administered corticosteroid when CMV reactivated (42.9% vs 0.0%, p=0.063). [Conclusion] TCR repertoire of CMV-CTLs at the time of CMV reactivation after SCT is highly oligoclonal and frequently shared among different patients, but can dynamically change in a short period in some patients. Functional analyses of the dominant TCRs to understand their reactivity against CMV epitope and elucidation of the clinical significance and developmental mechanisms of clone shift are strongly warranted. Figure Disclosures Kitaura: Repertoire Genesis Inc.: Employment. Suzuki:Repertoire Genesis Inc.: Equity Ownership.
15
Kishida, Yuya, Yuho Najima, Yuki Otsuka, Kenya Toma, Atsushi Wada, Hiroto Adachi, Ryosuke Konuma, et al. "Post-Transplant Maintenance Treatment with Ponatinib for Philadelphia Chromosome Positive Leukemia." Blood 134, Supplement_1 (November 13, 2019): 5694. http://dx.doi.org/10.1182/blood-2019-128031.
Full textAbstract:
[Background] Philadelphia chromosome positive (Ph+) leukemia is characterized by highly proliferative nature and clone instability that evokes the emergence of mutated clones, including BCR-ABL1 T315I mutated clone. Established evidence on the use of tyrosine kinase inhibitors (TKIs) after allogeneic hematopoietic stem cell transplantation (HSCT) is still lacking. The use of second-generation TKIs as a maintenance treatment after HSCT has been studied, and it is expected that their use would improve the prognosis by suppressing recurrence. The advent of ponatinib (PON), a potent inhibitor of tyrosine kinase including T315I mutated BCR-ABL1, is expected to improve clinical outcome of Ph+leukemia. However, there are few reports of a maintenance treatment using PON after HSCT. [Methods] We retrospectively reviewed data of 13 patients (pts) who received PON for Ph+leukemia after HSCT while in hematological complete remission (CR) between April 1, 2016 and July 15, 2019. Prophylactic treatment (Pro) was defined as post-transplant administration of PON while in minimal residual disease (MRD) negative CR. Pre-emptive treatment (Pre) was defined as starting PON when the bcr-abl transcript was detected by either quantitative or nested qualitative PCR after HSCT. ABL1 mutation was analyzed through the direct sequencing method. Adverse events were evaluated according to the Common Terminology Criteria for Adverse Events version 5.0. Overall survival (OS) was estimated using Kaplan-Meier method. Non-relapse mortality (NRM) and cumulative incidence of hematological relapse (CIR) were calculated using Gray's test. This study protocol was approved by the ethics committee of Tokyo Metropolitan Komagome Hospital. [Results] Underlying diseases were Ph+ALL in 8 pts (5 in CR, 3 in non-CR at HSCT), CML in 5 (all in second chronic phase). ABL1 mutations were analyzed in 12 pts and T315I mutation was detected in 4 pts with Ph+ALL and 2 with CML. Furthermore, compound mutations (CMs) in BCR-ABL1 were detected in 4 pts before HSCT. PON was used in 6 only after HSCT, and in 7 both before and after HSCT. During the median observation after HSCT of 584 days (range, 116-1,110) for survivors, no vascular occlusion event occurred. With regard to adverse events (AEs), grade 3 AEs occurred in 2 pts (15.4%) and no grade 4 AE was observed. Two had liver dysfunction and one of them discontinued PON due to grade 3 abnormalities in liver function tests. One suffered from grade 3 thrombocytopenia. Four had skin rashes lower than grade 3 that were indistinguishable from skin graft-versus-host disease, and all of them resolved through topical steroid therapy. Of all, 6 were in Pro group and 7 were in Pre group. The initial dose of PON was median 15mg (range 45mg/twice a week - 15mg/day) in Pro and median 30mg (range, 15-45mg) in Pre. The median days from HSCT to the start of PON was 107 days (range, 32-174) in Pro and 208 days (range, 50-364) in Pre. The median duration of PON treatment was 297 days (range, 20-699) in Pro and 188 days (range, 5-608) in Pre. At final observation in Pro group, 2 pts relapsed and died during the salvage therapy, 1 pt discontinued PON due to hepatic adverse event, and 3 pts were still on PON. Meanwhile, in Pre group, 5 pts achieved MRD negative CR after PON administration (1 pt also received donor lymphocyte infusion and stop PON due to liver dysfunction, 1 discontinued PON by the patient's request, and 3 of them were still on PON). One pt with CM relapsed but achieved CR through salvage therapy and 1 pt with low performance status (KPS 60) died at home of unknown cause six days after taking PON 30mg daily. For all the 13 pts receiving PON maintenance therapy, OS was 74.6% (95%CI; 39.8-91.1), CIR was 23.1% (95%CI; 5.1-48.5), and NRM was 7.7% (95%CI; 0.4-30.6) at 1 year after transplant (Figure 1). Two out of 4 pts with CMs (V299L/F317L and E255K/T315I/F317L) remains in MRD negative CR. The other 2 with CMs (E255K/T315I and D276G/T315I) had progressed to hematological relapse, suggesting the resistance to PON. In contrast, only one out of 9 without CMs relapsed on PON treatment. [Conclusion] Our results suggested that post-transplant maintenance treatment using PON was tolerable in the majority of patients with Ph+leukemia, although the optimal dose or the initiation strategy (Pre or Pro) are still undetermined. Furthermore, some patients with T315I-inclusive CMs seemed to be resistant to PON. The longer observation in a larger cohort is warranted. Disclosures No relevant conflicts of interest to declare.
16
Hara, Kentaro, Haruhiko Cho, Atsushi Onodera, Kazuya Endo, Yukio Maezawa, Toru Aoyama, Takanobu Yamada, Takashi Oshima, and Yasushi Rino. "Long‐term treatment outcomes in gastric cancer with oligometastasis." Annals of Gastroenterological Surgery, August 31, 2023. http://dx.doi.org/10.1002/ags3.12733.
Full textAbstract:
AbstractAimWhile surgery is essential for curative treatment of gastric cancer with oligometastasis, its target, timing, and possibility of combination with other treatments are unclear. We herein investigated the clinical course and long‐term outcomes of gastric cancer with oligometastasis in the real world setting to determine the optimal therapeutic strategy.MethodsThe present study retrospectively analyzed 992 patients who received any treatment for metastatic or recurrent gastric adenocarcinoma at Tokyo Metropolitan Komagome Hospital between 2007 and 2019. Oligometastasis was defined as any one of the following: liver metastases (HEP) <3; lung metastases (PUL) <3; unilateral adrenal gland metastasis (ADR); para‐aortic lymph node metastasis (PALN); or one, distant, lymph node metastasis, excluding the regional lymph nodes (LYM). Overall survival was compared by the characteristics and treatments for the oligometastasis, and univariate and multivariate analyses were used to identify the prognostic factors of overall survival.ResultsNinety‐seven patients (9.8%) with the following metastasis sites were enrolled: HEP (n = 27), PUL (n = 2), ADR (n = 3), PALN (n = 55), and LYM (n = 10). The median survival time of the cohort was 22.8 months, and the five‐year overall survival rate was 28.4%. On multivariate analysis, chemotherapy for the initial treatment (hazard ratio [HR]: 0.438; p = 0.048), distal gastrectomy and/or metastasectomy (HR: 0.290; p = 0.001), and R0 resection (HR: 0.373; p = 0.005) were identified as independent, positive factors of overall survival.ConclusionThe long‐term outcomes of gastric cancer in patients with oligometastasis may improve if treatment is begun with chemotherapy rather than surgery.
17
Zhang, Xian-Da, Yao Zhang, Yi-Zhou Zhao, Chun-Hua Zhou, and Duo-Wu Zou. "Autoimmune pancreatitis: A bibliometric analysis from 2002 to 2022." Frontiers in Immunology 14 (February 22, 2023). http://dx.doi.org/10.3389/fimmu.2023.1135096.
Full textAbstract:
Background/ObjectivesAutoimmune pancreatitis (AIP) is a distinct form of pancreatic inflammatory disease that responds well to glucocorticoid therapy. Knowledge on AIP has rapidly evolved over the past two decades. Based on bibliometric analysis, this study aimed to assess the research status of AIP over the past two decades and determine the research focus and emerging topics.MethodsAIP-related publications published between January 1, 2002, and June 6, 2022, were retrieved from the Web of Science Core Collection. Bibliometric data were analyzed using HisCite, VOSviewer, CiteSpace, and bibliometrix package. Annual output, leading countries/regions, active institutions and authors, core journals and references, and keywords of AIP were evaluated.ResultsOverall, 1,772 publications were retrieved from 501 journals by 6,767 authors from 63 countries/regions. Japan published articles on AIP the most (n=728, 41.1%), followed by the United States (n=336, 19%), Germany (n=147, 8.3%), China (n=127, 7%), and Italy (n=107, 6%). The top three most prolific authors were Terumi Kamisawa from Tokyo Metropolitan Komagome Hospital (n=117), Kazuichi Okazaki from Kansai Medical University (n=103), and Shigeyuki Kawa from Matsumoto Dental University (n=94). Pancreas was the most productive journal regarding AIP research (n=95), followed by the Journal of Gastroenterology (n=67), Internal Medicine (n=66), Pancreatology (n=63), and World Journal of Gastroenterology (n=62). “Diagnosis” was the most mentioned keyword. “Risk,” “malignancy,” “outcome,” “22-gauge needle,” and “fine-needle aspiration” were recognized as emerging topics.ConclusionJapan was the leading country in AIP research. Research papers were mainly published in specialized journals. Diagnosis was the research focus. Long-term outcomes and pancreatic tissue acquisition were recognized as research frontiers for AIP.
18
"Simple fluorescent EIA for detection and quantification of hepatitis C viremia 1) Tokyo Metro. Komagome Hosp. Japan. 2) Univ Florida College of Medicine, USA. 3) Nagoya City Univ., Japan. 4) Shinshu Univ. Japan. 5) Tokyo Metro Inst Medi Sci Japan. 6) Intern Reagents Co., Japan. 7) Tonen Co., Japan." Hepatology 22, no. 4 (October 1995): A355. http://dx.doi.org/10.1016/0270-9139(95)95144-x.
Full text
19
"Significance of serum hepatitis C virus core protein level in patients with chronic hepatitis C , 1Department of Medicine, Nagoya City University of Medical School, Nagoya, Japan, 2Section of Hepatobiliary Diseases, University of Florida, USA. 3Liver Unit, The Metropolitan Komagome Hospital, Japan, 4Department of Microbiology, The Tokyo Metropolitan Institute of Medical Science, Japan." Hepatology 22, no. 4 (October 1995): A469. http://dx.doi.org/10.1016/0270-9139(95)95599-2.
Full text